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A novel treatment of cystic fibrosis acting on-target:
cysteamine plus epigallocatechin gallate for the
autophagy-dependent rescue of class II-mutated CFTR
A Tosco1, F De Gregorio1, S Esposito2, D De Stefano2, I Sana2, E Ferrari2, A Sepe1, L Salvadori1, P Buonpensiero1, A Di Pasqua1,
R Grassia3, CA Leone3, S Guido4, G De Rosa5, S Lusa6, G Bona7, G Stoll8,9,10,11, MC Maiuri9, A Mehta12, G Kroemer*,9,13,14,15,16,17,
L Maiuri*,2,7 and V Raia*,1
We previously reported that the combination of two safe proteostasis regulators, cysteamine and epigallocatechin gallate (EGCG),
can be used to improve deficient expression of the cystic fibrosis transmembrane conductance regulator (CFTR) in patients
homozygous for the CFTR Phe508del mutation. Here we provide the proof-of-concept that this combination treatment restored
CFTR function and reduced lung inflammation (Po0.001) in Phe508del/Phe508del or Phe508del/null-Cftr (but not in Cftr-nullmice),
provided that such mice were autophagy-competent. Primary nasal cells from patients bearing different class II CFTR mutations,
either in homozygous or compound heterozygous form, responded to the treatment in vitro. We assessed individual responses to
cysteamine plus EGCG in a single-centre, open-label phase-2 trial. The combination treatment decreased sweat chloride from
baseline, increased both CFTR protein and function in nasal cells, restored autophagy in such cells, decreased CXCL8 and TNF-α
in the sputum, and tended to improve respiratory function. These positive effects were particularly strong in patients carrying
Phe508del CFTRmutations in homozygosity or heterozygosity. However, a fraction of patients bearing other CFTR mutations failed
to respond to therapy. Importantly, the same patients whose primary nasal brushed cells did not respond to cysteamine plus EGCG
in vitro also exhibited deficient therapeutic responses in vivo. Altogether, these results suggest that the combination treatment of
cysteamine plus EGCG acts ‘on-target’ because it can only rescue CFTR function when autophagy is functional (in mice) and
improves CFTR function when a rescuable protein is expressed (in mice and men). These results should spur the further clinical
development of the combination treatment.
Cell Death and Differentiation (2016) 23, 1380–1393; doi:10.1038/cdd.2016.22; published online 1 April 2016
Cystic fibrosis (CF), the most common lethal recessive
disease in Caucasians, affects ~ 70 000 subjects worldwide
and results from mutations in the cystic fibrosis transmem-
brane conductance regulator (CFTR).1,2 Mutation-specific
CFTR-repairing therapies with a channel-potentiator (Ivacaf-
tor) are available for ~ 5% of CF patients bearing membrane-
resident class III mutants.3 In contrast, for the vast majority
of CF patients bearing the most common F508del-CFTR
mutation, an FDA-approved combined treatment with the
corrector Lumacaftor (that promotes ER to plasma membrane
(PM) traffic) and Ivacaftor is marginally effective.4–7 F508del-
CFTR is retained in the endoplasmic reticulum (ER) and
prematurely degraded before it reaches the PM.8 Besides a
gating defect,8 F508del is unstable and rapidly dismissed from
the PM even upon treatment with correctors. When Ivacaftor is
combined in vitro with CFTR correctors, the former counter-
acts the latter by further decreasing F508del-CFTR PM
stability after rescue.9,10 This might explain the marginal
clinical effects of this combination in F508del-CFTR patients4
as it fails to reverse sweat test, a surrogate marker of disease
reversal,11,12 consistent with putative ‘off-target’ effects.
Discordance in therapeutic response rate complicates
mutation-specific approaches. Existing candidate drugs, as
Lumacaftor, fail to act on other class II mutants,13,14 show poor
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efficacy in vitro and lack of benefit in vivo5 in CF patients
bearing only one copy of F508del. This indicates that a
different rationale is needed based on mechanistic rather than
mutation-specific approaches, and suggests strategies focus-
ing on individual and not average responses to therapy.13
Recent results suggest that CFTR orchestrates a proteo-
static network that influences multiple cellular functions by
acting as a hub protein.15 This hub-dysfunction model
proposes that the proteostasis network is widely deranged,
both in transgenic CF mice and in primary epithelial cells from
F508del-CFTR homozygous patients, at two levels. First,
autophagy, the major mechanism determining cytoplasmic
protein turnover, is blocked owing to tissue transglutaminase
(TG2)-mediated depletion of the essential autophagy-related
protein Beclin 1 (BECN1), leading to secondary accumulation
of the autophagic substrate SQSTM1/p62.16 Second, peptide
fragments released from proteolytically cleaved F508del-
CFTR provoke an overactivation of the pleiotropic protein
kinase CK2, which in turn contributes to F508del-CFTR
degradation.17 Combined inhibition of both TG2 by the
repurposed cysteamine, FDA-approved for the treatment of
cystinosis,18,19 (which reestablishes autophagy) and over-
active CK2 by the over-the-counter green-tea flavonoid
epigallocatechin gallate (EGCG) synergize in vitro and
thereby rescue and stabilize, respectively, a functional
F508del-CFTR protein at the PM, both in mice and in primary
nasal cells from F508del-CFTR homozygotes.20 This
prompted a pilot trial combining cysteamine and EGCG in
ten F508del-CFTR homozygotes, showing that the combina-
tion treatment was well tolerated, reverted sweat chloride
toward normal and significantly attenuated biomarkers of
airway inflammation.20
Here, we provide new insights from newly generated
transgenic mice and patients primary cells and investigate
in a phase-2 clinical trial the individual patient responsiveness
to a combination of cysteamine plus EGCG in CF patients
bearing different classes of CFTR mutation. Moreover, we
evaluate the feasibility of using both functional and mechan-
istic biomarkers as a prediction test of patient responsiveness
to facilitate a future personalized approach to precision CF
therapy.
Results
Proof-of-concept studies in mice. To provide the proof-of-
concept for the use of cysteamine plus EGCG in CF patients
bearing one copy of F508del-CFTR and another severe
CFTR mutation with negligible residual CFTR activity,
F508del-CFTR homozygous mice (CftrF508del/F508del) were
backcrossed with transgenic knockout (KO) Cftr mice (Cftr− /−)
to obtain F508del/null CFTR heterozygous mice (CftrF508del/− ).
Mice were gavaged with cysteamine or EGCG alone or
cysteamine plus EGCG for 5 days followed by EGCG alone
or vehicle for further 2 weeks.20 The primary end point of this
mouse trial (Supplementary Figure S1) was the rescue of
CFTR function and protein. Secondary end points were the
restoration of BECN120–22 and the reduction of Cxcl2
(chemokine[C-X-C motif]-ligand 2) and Tnf-α (tumor necrosis
factor) transcripts in lung homogenates.
Cysteamine alone or combined with EGCG (but not EGCG
alone) restored rectal potential difference (RPD) responses to
forskolin in vivo to mean 79.4% (95% confidence interval (CI):
68.1–90.8%) of WT controls in CftrF508del/F508del mice and
84.7% (77.5–91.8%) in CftrF508del/− mice (Po0.001) (Figure
1a and b). The treatment significantly improved the forskolin-
induced increase in short-circuit current (Isc) in mouse ileum
mounted in Ussing chambers to 130% (123.6–136.4%) and
138.7%, (130.4–147.0%) of WT controls (Po0.001), respec-
tively, which was partially reverted by a selective CFTR
inhibitor, CFTRinh172 (Figure 1d and e), indicating that CFTR
function was restored by the treatment. The inability of Cftr−/−
mice to mount a similar response to cysteamine (Figure 1c
and f) indicated that mutated CFTR protein is indispensable
for therapeutic effect. No effects of cysteamine or EGCG on
CFTR function were observed in WT mice (Figure 1h and
Supplementary Figure S2). Cysteamine alone or combined
with EGCG, but not EGCG alone, rescued mature CFTR
protein (band C) expression to 450% of WT values and
restored BECN1 expression in intestinal homogenates from
either CftrF508del/F508del and CftrF508del/− (Figure 2a), whereas
no CFTR protein was detected in intestine from Cftr− /− mice,
regardless of treatment (Figure 2b).
To determinewhether the effects of cysteamine on F508del-
CFTR rescue were linked to its capacity to restore autophagy,
we obtained CftrF508del/F508del mice in Becn1 haploinsufficient
background (CftrF508del/F508del/Becn1+/− ). Cysteamine lost its
therapeutic efficacy in CftrF508del/F508del Becn1+/– mice (Figure
1g-i and Figure 2c), supporting the importance of BECN1-
dependent autophagy for drug effects.
The combination treatment significantly reduced Cxcl2
and Tnf-α mRNA levels in lung homogenates from
CftrF508del/F508del and CftrF508del/− mice (Figure 2d). All the
responses observed in these mice were maintained for 2 weeks
beyond cysteamine withdrawal, provided that EGCG treatment
wasmaintained during this period (Po0.001 versusmice treated
with vehicle during cysteamine withdrawal) (Figures 1 and 2).
Taken together, proof-of-concept data supported the feasi-
bility of treating autophagy-competent mice expressing at
least one F508del-CFTR allele by a combination of cystea-
mine and EGCG.
Human studies. To translate preclinical data in humans,
52 consenting CF patients were sequentially enrolled at
Regional Cystic Fibrosis Care Center, University of Naples
Federico II, in a phase-2 clinical trial. Patients were F508del
homozygous or compound heterozygous for (i) F508del or
another class II mutation on one allele and a severe CFTR
mutation with minimal residual CFTR activity (class I or II) on
the other allele or (ii) class I mutations on both alleles
(negligible CFTR synthesized). Schedule of treatment com-
prised oral cysteamine alone for 8 weeks, followed by
cysteamine plus EGCG for further 4 weeks (or 8 weeks in
a subgroup of 10 F508del-CFTR homozygous patients)
followed by EGCG alone for additional 8 weeks (Figure 3).
Throughout, all subjects continued their pre-study medica-
tion. Forty-two of 52 subjects who accepted the treatment
schedule were assigned to three different cohorts by
genotype, whereas 10 who declined treatment schedule, all
bearing F508del or other class II CFTR mutations, were
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allocated to the untreated ‘standard-of-care’ control group
(cohort 4) to follow the natural history of disease during an
overlapping period. Baseline characteristics of study popula-
tion and scheduled visits are reported in Supplementary
Tables S1–S5.
In vitro studies before in vivo treatment: Before in vivo
treatment, primary nasal epithelial cells freshly collected by
nasal brushing at baseline were challenged in vitro with
cysteamine and/or EGCG, and then kept in culture with
medium alone or EGCG up to 48 h.20 The combination
treatment in vitro restored both CFTR function and CFTR
band C protein in PM fractions up to 450% of non-CF
controls in all but one patient bearing at least one class II
mutation. F508del homozygous patients were responsive, as
described,20 whereas all subjects bearing two class I
mutations were unresponsive. The effects of combination
treatment in vitro in class II patients persisted up to 48 h
following cysteamine washout, provided that EGCG was
maintained in the culture medium (Figure 4, Supplementary
Table S6).
In vivo treatment: In total, 88.5% of patients completed the
study. Mean adherence to treatment was 93.8%. Given the
short half-life of cysteamine, data from two patients with
adherence o60% were excluded. The pharmacokinetic
profile of cysteamine was as described in our pilot trial
(Supplementary Figure S3).20 The incidence of adverse
events was comparable to that observed in cysteamine-
treated cystinosis (Supplementary Tables S7–S11).
Treatment efficacy. The primary end point was the change in
CFTR function, measured by a two-site assessment: decrease
of sweat chloride values from baseline of 415% coupled to
increase of CFTR function and CFTR band C protein in nasal
epithelial cells of 415% of non-CF controls. Secondary end
points were (i) restoration of autophagy in nasal brushing
(mechanistic end point biomarkers); (ii) reduction from base-
line of inflammatory cytokines in both nasal cells and sputum
(biomarker of organ inflammation); (iii) absolute change from
baseline in percentage of predicted forced expiratory volume
at 1 s (ppFEV1) (marker of clinical efficacy).
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Figure 1 Proof-of-concept studies in mice: effects of treatment on CFTR function in CftrF508del/F508del, CftrF508del/− , Cftr−/− and CftrF508del/F508delBecn1+/– mice. Effects on
CFTR function of oral administration of different combinations of cysteamine and EGCG in CftrF508del/F508del (a and d), CftrF508del/− (b and e) and Cftr− /− (c and f) mice. The
different treatment schedules are indicated. (a–c) Rectal potential difference (RPD) in vivo in response to 20 μM forskolin (Fsk) (mean± S.D.); (d–f) CFTR-dependent Cl−
secretion measured by means of forskolin-induced increase of the chloride current (Isc (μA/cm
2)) ex vivo in the ileum mounted in Ussing chambers and effects of CFTR inhibition
(CFTRinh-172, abbreviated Inh) and amiloride (abbreviated Am) for each group of treatment (#Po0.001 versus vehicle-treated mice). (g–i) Effects of treatment on CFTR function
in Cftr+/+Becn1+/– (g), FVB/129Cftr+/+ (h) and CftrF508del/F508delBecn1+/– (i) mice. The different treatment schedules are indicated. CFTR-dependent Cl− secretion measured as
by means of forskolin-induced increase of the chloride current (Isc (μA/cm
2)) ex vivo in the ileum mounted in Ussing chambers and effects of CFTR inhibition (CFTRinh-172,
abbreviated Inh) and amiloride (abbreviated Am) for each group of treatment (#Po0.001 versus vehicle-treated mice). Eight-week-old mice, n= 10 per group of treatment.
Treatments: Cys, cysteamine; EGCG, epigallocatechin gallate; Cys+EGCG, 5 days treatment with cysteamine and EGCG; Cys+Wo+EGCG, 5 days treatment with cysteamine
and EGCG followed by 2 weeks of cysteamine washout in the presence of EGCG
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The study met the primary end point of efficacy. In the
34 treated patients who completed the study the com-
bined therapy reduced sweat chloride concentrations by
mean −18.0 mmol/liter (range, −66 to 21; 95% CI, −23.7,
−12.3 mmol/l), corresponding to mean −19.8% (−50 to
24.4%; 95% CI, −25.5; −14.1%) as compared with baseline
(Po0.0001, t-test treatment versus baseline) (Figure 5a,
Supplementary Figure S4) and increased CFTR function in
nasal cells from mean (95% CI) 5.8% (4.8, 6.7%) at week 0 up
to mean 20.9% (18.7, 23.1%) (expressed as percentage of
non-CF controls) after combination treatment (Po0.0001
versus baseline) (Figure 5b). Accordingly, the abundance of
band C CFTR protein increased from mean 9.9% (95% CI,
9.4, 10.5%) of non-CF control values to 60.5% (55.4, 65.7%)
after combined treatment (Po0.0001 versus baseline)
(Figure 5c,Supplementary Figure S5a). The increase percen-
tages of CFTR function and band C protein in nasal brushing
are strongly correlated (Pearson's correlation coefficient=0.61
with the associate P=0.0001). Notably, the percentage
change of sweat chloride is negatively correlated with change
in CFTR function in nasal cells (Pearson’s correlation
coefficient=−0.47 with the associated P=0.005, Spearman’s
correlation coefficient=−0.44 with P=0.009) (Figure 5d).
Changes of primary end points were negligible in the
untreated cohort 4 throughout the study (P40.5 versus
baseline) (Figure 5a–c).
Regarding the secondary end points, the combination
treatment increased BECN1 levels in nasal cells from mean
(95% CI) 22.4% (21.9, 22.8%) of non-CF controls at the
baseline, up to 53.1% (49.6, 56.6%) and decreased SQSTM1/
p62 from mean 276.3% (274.1, 278.6%) of controls to 134.0%
(119.5, 148.6%) (Po0.0001 versus baseline) (Supplementary
Figure S5b). Moreover, in treated patients, CXCL8 (chemokine
[C-X-C motif]-ligand 8) and TNF-α mRNA levels in nasal
brushing and protein levels in the sputum significantly
decreased after combination treatment respect to baseline
(Po0.001) with a mean percentage (95% CI) decrease of
CXCL8 and TNF-α of −57.7% (−45.5, −69.9%) and −55.8%
(−45.5, −66.2%), respectively, in nasal cells and −45.6%
(−34.5, −56.7%) and −26.3% (−14.8, −37.9%) in the
sputum. Notably, cytokine expression remained attenuated
after 4 weeks following drug discontinuation (Figure 6a, d and
e,Supplementary Figure S6). Changes in either autophagy
markers or cytokine expression (Figure 6a) were negligible in
the untreated cohort 4 throughout the study.
In this short-term clinical trial (the effective combination
treatment covers 4 or 8 weeks of the 24-week study) a mean
absolute change from baseline, although not significant, of 3.2
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Figure 2 Proof-of concept studies in mice: effects of treatment on rescue of functional CFTR protein and lung inflammation in CftrF508del/− mice. (a) Representative
immunoblot with anti-CFTR (clone CF3 Abcam) and BECN1 (clone Ab55878) (top left) and densitometric measurement as fold increase respect to vehicle-treated mouse
normalized to β-actin levels (bottom left) in one CftrF508del/− mouse per treatment group; (right) assessment of CFTR-dependent Cl− secretion measured by means of forskolin-
induced increase of the chloride current (Isc (μA/cm
2)) ex vivo in the ileum mounted in Ussing chambers and effects of CFTR inhibition (CFTRinh-172, abbreviated Inh) and
amiloride (abbreviated Am) (right) in one mouse per treatment group. (b) Representative immunoblot with anti-CFTR (clone CF3 Abcam) (left) and assessment of CFTR-
dependent Cl− secretion (right) in one Cftr−/− mouse per treatment group. (c) Representative immunoblot with anti-CFTR (clone CF3 Abcam) (top) and densitometric
measurement (bottom) in one CftrF508del/F508delBecn1+/– mouse per treatment group mean± S.D. of independent measurements; #Po0.001 versus vehicle-treated mice
(ANOVA). (d) Effects of oral administration of cysteamine and EGCG on cytokine expression in lung homogenates from CftrF508del/− mice. The different treatment schedules are
indicated. Cxcl2 (left) and Tnf (right) mRNA levels in lung homogenates from 8-week-old mice (n= 10 per group of treatment). (*Po0.01, #Po0.001 versus untreated mice).
Cys, cysteamine; EGCG, epigallocatechin gallate; Cys+EGCG, 5 days treatment with cysteamine and EGCG; Cys+Wo+EGCG, 5 days treatment with cysteamine and EGCG
followed by 2 weeks of cysteamine washout in the presence of EGCG; Cys+EGCG+Wo, 5 days treatment with cysteamine and EGCG followed by 2 weeks of washout of both
cysteamine and EGCG
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in ppFEV1 (95% CI, 0.2, 6.3) was observed after combination
treatment and tended to increase at the post-treatment visit
(Figure 6b). The increase was greater (6.2 (95% CI, 1.0, 11.4))
in the subgroup of patients (subgroup A of cohort 1) who
received combination treatment for 8 weeks (Figure 6c). By
contrast, negligible mean changes of –0.7 (95% CI, −4.7, 2.8)
were observed in the untreated group (Figure 6b).
Individual responsiveness to treatment. Given the well-
known inter- and intra-individual variability of either
ppFEV1
23 or sweat chloride concentrations,24 and the discor-
dance in response rate to treatment even in patients with
the same genotype,25,26 we assessed the individual patient
responsiveness to treatment by analyzing the proportion of
patients who met primary end point criteria. We pre-specified
that two criteria must be simultaneously fulfilled to define
responsiveness: (1) decrease of sweat chloride concentra-
tions to values below −99% CI from mean individual values
during the preceding 24 months, including week – 0 value; 2)
increase of both CFTR function and band C protein in nasal
cells to 415% of non-CF controls. Next, we analyzed the
proportion of participants who had fulfilled the primary end
point (referred to as responders), who also show:
(i) autophagy rescue in nasal cells (BECN1 450% of non-
CF controls and SQSTM1/p62 levels o50% from baseline);
(ii) decrease of CXCL8 and/or TNF-α levels in nasal cells
and/or sputum by430% from baseline; (iii) absolute change
from baseline in ppFEV1. Individual values are shown in
Figure 5e, and Figures 6d,e and 7, Supplementary Figure S7
and Supplementary Tables S12–13.
Among 34 treated participants, 26 (76.5%) fulfilled compo-
site primary end point criteria after combination treat-
ment. Sweat chloride fell below 60 mmol/liter in eight
subjects bearing at least one class II mutation (Figure 5e).
Patients bearing class I mutations on both alleles were
non-responders. None of untreated participants met the
74 patients were assessed for eligibility
22 declined to participate 
Cohort 1
24 F508del/F508del
10 Analyzed 
52  gave signed consent 
Cohort 4 
Class II/other *
10 Completed 
the study
8  Analyzed
2 Excluded from 
the analysis 
because of low 
adherence to 
treatment
3 Discontinued 
3 Due to AE
Cohort 3 
9 other*/other*
Cohort 2
9 F508del/other*
2 Discontinued 
1 Due to AE
1 Refused       
further dosing     
1 Discontinued 
1 Due to AE
7 Completed the 
study
8 Completed the 
study
10 Completed 
the study
7  Analyzed
Subgroup 1A§
10 Cys +EGCG 
treatment
for 8 weeks
Subgroup 1B
14 Cys +EGCG 
treatment
for 4 weeks
9 Cys + EGCG 
treatment
for 4 weeks
9 Cys + EGCG 
treatment
for 4 weeks
10 No 
treatment 
10  Analyzed
11 Completed 
the study
9  Analyzed
Week 0 Week 8 Week 16  Week 24 Week 12 Week 20 
EGCG
Cys (q6h) plus
EGCG 
NO TREATMENT
EGCG
EGCG
EGCG
No 
treatment
No 
treatment
No 
treatment
Cohort 1A  N=10
Cys (q6h)
Cohort 1B  N=14  
Cohort 4    N=10
Cys (q6h)
Cys (q6h)
Cys (q6h)
Cohort 3    N=9  
Cohort 2    N=9  
No 
treatment
Week 28 
Cys (q6h)  
Plus EGCG 
Cys (q6h)  
Plus EGCG 
Cys (q6h)  
Plus EGCG 
Figure 3 Study profile and study design. Other*=Class I or II mutations. § Patients (Subgroup 1A, N= 10) had already participated to the first part of the study and were
enrolled after at least 4 months of washout when all laboratory and clinical parameters returned at the values registered prior study. Dosage: cysteamine:o12 years: 900 mg/die
in four doses;412 years: 1200 mg/die in four doses. EGCG: 270 mg/die in one dose. AE, adverse events; Cys, cysteamine; EGCG, epigallocathecin gallate
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composite primary end point criteria throughout the study
(Fisher's test Po0.001 versus treated subjects). Only three
responders (all bearing F508del) met the criteria after the first
8 weeks of treatment with cysteamine alone (Fisher's test
P= 0.5 versus untreated patients). Autophagy in nasal cells
was restored in all responders after combination treatment
but in none of untreated participants throughout the study
(Fisher test Po0.001).
In 23 of 26 responders, at least two of either nasal or sputum
CXCL8 and/or TNF-α levels decreased by 430% from
baseline after combination treatment. None of untreated
subjects manifested a similar decrease versus baseline
(Fisher's test, P o0.01 versus treated subjects) (Figure 6d
and e).
In 13 out of 34 treated patients (but in none of the untreated
patients, Fisher's test P=0.021) the increase in ppFEV144
(relative to baseline) achieved at the end of the combination
treatment, was conserved at the post-treatment visit
(Table 1). Ten of them belong to the 26 responders, and
other 2 (no. 12 and 27, Table 1) met all the sequential steps of
responsiveness, except for the sweat test, i.e., restoration of
functional CFTR protein and autophagy coupled to stable
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least 50 cells per sample and per experiment. (b) Individual values of residual CFTR protein at the PM of CF patients in different cohorts. The values are expressed as percent of
five non-CF healthy control. Mean values of independent experiments. Black line represents the mean value. Cys, cysteamine; EGCG, epigallocatechin gallate; Wo, washout.
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decrease of inflammatory biomarkers. Six of them (No. 1, 2,
5, 8, 9, 10 of Table 1) received combination treatment for 8
instead of 4 weeks (subgroup A of cohort 1). This is
consistent with preclinical data in mice demonstrating that
the beneficial effects of treatment are maintained for several
weeks after drug withdrawal. Notably, the occasional (at one
single visit) changes in ppFEV1 in untreated cohort were
never coupled to a decrease of inflammatory cytokines nor to
restoration of CFTR function or autophagy (Table 1). To look
at causal relationship between improvement in ppFEV1 at the
end of combination treatment and at the last post-treatment
visit, a linear regression model was inferred. A positive
regression coefficient was obtained (0.8) with an associated
P=0.000135.
Predictive value of biomarkers. Personalized approaches
to treatment require biomarkers as either (i) predictors of
putative individual responsiveness before treatment or
(ii) early detectors of efficacy during treatment before clinical
benefits become evident.
Analysis of biomarkers in vitro before treatment: In all but
one treated patients, in vitro challenge of nasal cells at week
0 with cysteamine plus EGCG restored both CFTR function
and band C protein in PM fractions up to 450% of non-CF
controls. All responders to the treatment in vivo manifested a
rescue to 450% of CFTR function and protein in vitro
(sensitivity: 100%), whereas 25/29 (86.2%) patients who
responded in this way in vitro were also responders in vivo.
Thus, rescuing 450% of functional CFTR protein in vitro
could support the clinical decision to treat in the future with a
negative predictive value of 100% and a positive predictive
value of 86.2% (sensitivity 100%, specificity 50%). Therefore,
a biomarker for treatment response in vivo could include
absolute changes in CFTR protein levels (Supplementary
Figure S8, see ROC curve).
Analysis of biomarkers during in vivo treatment: The restora-
tion of CFTR function, as measured ex vivo during in vivo
treatment, could be a useful tool to monitor the therapeutic
responsiveness before stable beneficial effects on lung
inflammation or clinical parameters become evident. The
restoration of CFTR function was present in 12/13 (99.3%)
patients who manifested a stable control of inflammation
coupled to an absolute increase of ppFEV144 percentage
points that is maintained at the end of the study.
Discussion
Our results challenge the currently accepted model that CF is
a mere channelopathy that must be treated with agents
directly acting on CFTR. The data provide the first evidence
that targeting the abnormal proteostasis network results in
CFTR repair coupled to clinical benefit in CF patients bearing
at least one copy of class II CFTRmutation, including F508del,
whereas it is not effective in subjects carrying two class I
mutations. This effect can be obtained by two proteostasis
regulators, the repurposed drug cysteamine, and the safe
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nutraceutical EGCG, which target two key nodes of misman-
aged proteostasis in CF, disabled autophagy and CK2
overactivation.
The effects of treatment are consistent with our mechanistic
animal data showing that this combination treatment is
not effective in Cftr-null mice (no protein rescuable), whereas
it is similarly effective in mice bearing one or two copies of
F508del-CFTR, provided that F508del-CFTR mice are auto-
phagy-competent (no effect in CftrF508del/F508del/Becn1+/−
mice). In addition, cell-based pre-treatment data in patient's
primary nasal cells support the use of combination treatment
in patients bearing other severe class II mutations, including
N1303K or G85E.
The primary efficacy end point of our clinical study was the
restoration of CFTR function in two organs (airways and sweat
duct). A short-term treatment with cysteamine plus EGCG, but
not with either alone, decreased baseline sweat chloride
concentrations by ~ 20% while restoring functional CFTR
protein up to ~ 20% of non-CF controls in nasal cells. The
combination treatment reversed the pathogenic cascade of
disease as it re-established autophagy in nasal cells,
indicating that drugs act ‘on-target’, in agreement with the
hypothesis underpinning our drug design. The restoration of a
functional CFTR protein is clinically relevant, as it significantly
reduces inflammation markers and increases FEV1 predicted
from baseline, even beyond the treatment period.
Personalized medicine is in vogue27–30 and CF is a
paradigm of heterogeneity in patient response to
treatments.25 Pooled analysis in large-scale trials might not
consider such variability, thus entailing the need of patient-
centered approaches to assess drug efficacy. Testing patient's
responsiveness to treatment using surrogate markers may
help to predict individual responsiveness at the clinical level.
In total, 76.5% of treated patients were responders to the
combination treatment, whereas none of untreated partici-
pants met these criteria throughout the study. The genotype
determined the likelihood of response as all responders
carried at least one copy of F508del-CFTR or other class II
mutations, but none of them carried two class I CFTRmutants.
CF is characterized by unresolved inflammation.31 After the
combination treatment, 88.4% of responders showed 430%
decrease of inflammatory cytokines that was retained at the
last post-treatment visit, in agreement with mouse data. The
prolonged control of lung inflammation may pave the way for
the effect of treatment on lung function. Six of 10 patients who
received the combination treatment for 8 weeks, retained
major clinical benefit until the last post-treatment visit,
CXCL8 treated TNF treated CXCL8 untreated TNF untreated
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4 weeks of combined therapy
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suggesting a clinical benefit increasing over time within a
stably un-inflamed environment.
Testing putative individual responsiveness to treatment by
appropriate biomarkers before in vivo therapy should support
the decision to treat. We show that restoring CFTR function
in vitro in nasal cells in response to cysteamine plus EGCG is
highly predictive of whether the combination treatment will
restore CFTR function in vivo. Biomarkers of autophagy
may add value to monitoring treatment efficacy in patients,
according to the supposed mechanism of action. Hence, this
in vitro assay may constitute a tool to guide the clinical
development of CF treatments, allowing to identify patients
who may profit from therapeutic options as the one that we
detail here.
Our data indicate sweat test as feasible surrogate biomarker
of CFTR function, provided that standardized procedures are
respected to reduce intra-individual variability. Sweat chloride
changes exhibit significant inverse correlation with CFTR
function in nasal cells. Although more variable than CFTR
measurements in nasal cells, sweat test should be recom-
mended in clinical trials aimed at CFTR repair.
Our novel therapy results from long-term academic
research aiming at refining disease-relevant targets for the
action of safe/repurposed drugs. Our combination has another
major advantage over existing channel-centered therapies for
F508del-CFTR as it is well tolerated and affordable, potentially
costing 410-fold less than currently approved drugs. Thus,
our affordable safe drug-repurposing strategy will likely set the
bar for future clinical trials aiming at repairing CFTR defect.
Our study has some limits mainly related to the small
sample size. To compensate for the small number, we
selected objective stringent biomarkers of efficacy that likely
would not be affected by randomization. The short duration of
treatment does not allow to determine the long-term clinical
benefit, although patients who had a persistent better clinical
benefit had received a longer period of combination treatment.
Further placebo-controlled trials on a larger population sample
will be required to assess the long-term effects of this
combination therapy, especially with respect to pulmonary
function, physical and cognitive performance and subjective
well being.
Materials and methods
Mouse studies
Mice and treatments: CF mice homozygous for the F508del-CFTR in the
FVB/129 outbred background (Cftrtm1EUR, F508del, FVB/129, abbreviated
CftrF508del/F508del, were obtained from Bob Scholte, Erasmus Medical Center
Rotterdam, The Netherlands, CF coordinated action program EU FP6 LSHM-
CT-2005-018932).32 Transgenic KO Cftr mice (B6.129P2-KOCftrtm1UNC, abbreviated
Cftr− /−), were purchased from The Jackson Laboratory (Bar Harbor, Maine, USA).33
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The heterozygous CftrF508del/+ males were backcrossed with the heterozygous
Cftr+/− females to obtain F508del/null CFTR heterozygous mice (abbreviated
CftrF508del/− ). CftrF508del/+ female mice were backcrossed to the C57BL/6J
background Becn1+/– male mice (generous gift from Beth Levine, Center for
Autophagy Research, Department of Internal Medicine, UT Southwestern Medical
Center, Dallas, USA and Francesco Cecconi, University of Tor Vergata, Rome,
Italy)34 to obtain at the first generation Becn1 haploinsufficient F508del
heterozygous mice (abbreviated CftrF508del/+/Becn1+/− ). These mice CftrF508del/
+/Becn1+/− were crossbred to obtain Becn1 haploinsufficient F508del homozygous
mice (abbreviated CftrF508del/F508del/Becn1+/− ). Mice for the study were aged
8-week-old.
Mice were gavaged with vehicle or cysteamine (60 μg/kg in 100 μl saline/day) or
EGCG (150 μg/kg in 100 μl saline/day) alone for 5 days or with cysteamine plus
EGCG for 5 days followed by EGCG alone or vehicle for further 2 weeks, as
reported.20
At the end of the treatment, mice were anesthetized with Avertine (tribromoethanol,
250 mg/kg, Sigma Aldrich, Milan, Italy, T48402) and a segment of tail was collected
for genotyping. Mice were then killed and lungs and intestines collected for analysis.
All the procedures in mice were approved by the local Ethics Committee for Animal
Welfare (IACUC No. 553 and 582) and were carried out in strict respect of European
and National regulations.
Genotyping of the new mouse models: The newly generated CftrF508del/−
and the CftrF508del/F508del/Becn1+/–were housed at the San Raffaele Scientific
Institute SOPF animal house (Milan, Italy). These mice were provided with a special
food, consisting of an equal mixture of SRM-A (Arie Blok, Woerden, The
Netherlands) and Teklad 2019 (Harlan Laboratories, San Pietro al Natisone, Udine,
Italy) and water acidified to pH 2.0 with HCl and containing 60 g/l PEG 3350, 1.46 g/l
NaCl, 0.745 g/l KCl, 1.68 g/l NaHCO3 and 5.68 g/l Na2SO4. Newborn mice were
genotyped by cutting a small piece of tail 12 days after birth. DNA was extracted by
digesting tails with Direct PCR Lysis Reagent (Viagen, CA, USA) and 1 mg/ml
Proteinase K overnight at 56 °C. For CftrF508del/− two PCR reactions were performed.
For the CftrF508del/F508del mutation, thermocycling consisted of an initial polymerase
activation step at 95 °C for 5 min, amplification was performed with 30 cycles of 95 °C
for 1 min, 52 °C for 1 min and 72 °C for 1 min with a final extension at 72 °C for 2 min;
for the Cftr− −/− mutation thermocycling consisted of an initial polymerase activation
step at 94 °C for 3 min, amplification was performed with 30 cycles of 94 °C for 30 s,
57 °C for 30 s and 72 °C for 30 s with a final extension at 72 °C for 10 min. For
CftrF508del/F508del/Becn1+/–, after analyzing the CftrF508del/F508del mutation, the Becn1+/–
thermocycling consisted of an initial polymerase activation step at 95 °C for 4 min,
amplification was performed with 30 cycles of 95 °C for 1 min, 62 °C for 1 min and
72 °C for 1.30 min with a final extension at 72 °C for 10 min. The sequences of PCR
primers are reported in Supplementary Table S15.
Procedures
Measurement of RPD. RPD was measured as described.20 In brief, RPD was
measured with a protocol similar to that for nasal potential difference measurements
in humans, as described.35,36 Mice were anesthetized with Avertine (250 mg/kg).
RPD was sensed with a digital volthometer inserted for ~ 2 cm in the rectum.
Potentials were measured with respect to a subcutaneous 1 M NaCl-filled needle. A
second rectal tube was used for continuous perfusion of drug administration into the
rectum. The Cl− containing solution had the following composition: 145 mM NaCl,
4 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, 0.1 mM amiloride, at a final
pH 7.4. The Cl− -free solution had the following composition: 145 mM sodium
gluconate, 4 mM potassium gluconate, 4 mM calcium gluconate, 1 mM magnesium
gluconate, 10 mM HEPES, 0.1 mM amiloride, at a final pH 7.4. To assess CFTR
function in vivo, we evaluated the response of the RPD to the presence of forskolin
and luminal amiloride (100 μM, to block Na+-dependent RPD) in Cl− -free solutions,
as previously described.20
Ussing chamber. Chambers for mounting tissue biopsy were obtained from
Physiologic Instruments (model P2300, San Diego, CA, USA). Chamber solution
was buffered by bubbling with a mixture of 95% O2 and 5% CO2. Tissues were short
circuited using Ag/AgCl agar electrodes. Short-circuit current and resistance were
acquired or calculated using the VCC-600 transepithelial clamp from Physiologic
Instruments and the Acquire &Analyze2∙3 software for data acquisition (Physiologic
Instruments), as previously described.37,38 A basolateral-to-apical chloride gradient
was established by replacing NaCl with Na-gluconate in the apical (luminal)
compartment to create a driving force for CFTR-dependent Cl− secretion. CFTR
channels present at the apical surface of the epithelium (lumen side of the tissue)
were activated.
Real time and reverse transcript PCR analysis. The analysis was performed
as previously described.20,39,40 The specifications of primers are reported in
Supplementary Table S15.
Immunoblot analysis. Western blot analysis was performed as previously
described16,20,21,22 with antibodies against the following proteins: BECN1, CFTR,
β-actin, SQSTM1/p62. The densitometric analysis was performed by Image J
software and each data point was expressed as the mean± S.D. of independent
experiments. The antibodies specifications are reported in Supplementary
Table S16.
Human studies
Patients and study design. An open-label phase-2 clinical trial was
conducted between 12 March 2014 and 9 January 2015 at the Department of
Translational Medical Sciences, Regional Cystic Fibrosis Care Center, University of
Naples Federico II. The protocol of this study is an amendment of the study
registered with primary registry EU-CT, Eudract Number #2013-001258- 82 in order
to include CF patients bearing different CFTR mutations for the treatment with
cysteamine and EGCG. This amended study was approved by the Italian Agency of
Drug and independent institutional local Ethics Committee and was done in
compliance with the Good Clinical Practice Guidelines, the amended Declaration of
Helsinki, and regulatory requirements. Written informed consent was obtained from
all patients and/or their legal guardians.
Among 74 eligible patients in regular follow-up at the at the Department of
Translational Medical Sciences, Regional Cystic Fibrosis Care Center, University of
Naples Federico II, 52 consenting patients were sequentially enrolled.
Inclusion criteria were as follows: (i) diagnosis of CF with sweat chloride ⩾ 60
mmol/l and two CF causing mutations at CFTR gene molecular analysis; (ii) age ⩾ 6
years; (iii) genotype characterized by (a) F508del on both alleles; (b) F508del or
another class II mutation on one allele and a severe CFTR mutation with minimal
residual CFTR activity (class I or II) on the other allele or (c) class I mutations on both
CFTR alleles; (iv) FEV1 at least of 40% of predicted value for persons of their age, sex
and height.
Exclusion criteria were as follows: (i) treatment with glucocorticoids per os or via
inhalation at screening or within 4 weeks before screening visit; (ii) treatment with
oxygen; (iii) treatment with other experimental drugs; (iv) referred hypersensitivity
(local or general) to cysteamine or penicillamine prior study modifications of
therapeutic regimens in patients assuming macrolides, antiasthmatic, mucolytic
drugs, Dornase alfa and/or NSAIDs within 28 days before screening visit; (v) organ
transplantation; (vi) kidney (creatinine 2 × upper normal limit) or hepatic alterations
(ALTand/or AST 5 × upper normal limit) at screening visit; (vii) pregnancy or nursing
at screening visit; (viii) refusing to employ contraceptive methods during the study;
(ix) psychiatric pathologies or neurological diseases.
After enrollment, safety and efficacy were assessed by clinical and laboratory
tests, including nasal brushing, at baseline and at the end of each treatment schedule
(Figure 3). Additional assessments were undertaken 4 weeks after drug
discontinuation.
We recorded adverse events and clinical and laboratory results throughout the
study. Severe adverse events were registered. Pill counts were undertaken at several
time points during treatment to evaluate adherence.
Outcomes. Primary end point: (i) sweat chloride values o15% from baseline
coupled to (ii) CFTR function and CFTR band C protein in brushed nasal epithelial
cells 415% of non-CF controls.
Secondary end points: (i) restoration of autophagy in nasal cells (BECN1 protein
levels 450% of non-CF controls and SQSTM1/p62 o50% from baseline;
(ii) reduction from baseline of inflammatory cytokines in both nasal cells and
sputum; (iii) absolute change from baseline in the ppFEV1.
Composite criteria to define individual responsiveness to treatment::
Pre-specified criteria that must be simultaneously fulfilled to define individual
responsiveness to treatment:
(1) sweat chloride concentrations to values o− 99% CI from the mean of the
individual values measured within the preceding 24 months and including the value at
week 0;
(2) band C CFTR protein and CFTR channel function in brushed nasal epithelial
cells415% of healthy non-CF control values.
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Schedule of treatment. Active treatment comprised oral cysteamine
(cysteamine bitartrate, trade name Cystagon, Orphan Europe) with or without
EGCG (trade name Epinerve, SIFI Pharmaceuticals). Initially, Cystagon (900 mg/die
for patients ⩽ 12 years and 1200 mg/die for patients412 years in four divided
doses) was given alone for 8 weeks, followed by a combination of Cystagon (same
dose) with Epinerve (270 mg once daily) for further 4 weeks (or for 8 weeks in a
subgroup of 10 F508del-CFTR homozygous patients) followed by Epinerve alone
for additional 8 weeks (Figure 3). Throughout, all subjects continued their pre-study
medication.
Therapeutic formulation and dose administration of cysteamine and
EGCG: Cysteamine: each hard capsule contains 150 mg fixed of cysteamine (as
mercaptamine bitartrate). The other ingredients are microcrystalline cellulose,
starch, pregelatined, magnesium stearate/sodium lauryl sulfate, colloidal silicon
dioxide, croscarmellose sodium; capsule shells: gelatin, titanium dioxide, black ink
on hard capsules. The prescribed dose was taken four times a day, every 6 h, just
after or with food.
EGCG: each tablet contains 135 mg of EGCG. The other ingredients are
microcrystalline cellulose, calcium phosphate dibasic, silicon dioxide, magnesium
stearate, mono-diglyceride of fatty acids. The prescribed dose was taken fasting.
Pharmacokinetic analysis. Plasma cysteamine concentrations were mea-
sured in six F508del/F508del participants at week 8 before and 2, 4 and 6 h after a
single oral dose of cysteamine (300 mg). The methodologies of the analyses for
plasma cysteamine levels are described in Supplementary Materials.
Nasal brushing. Freshly isolated brushed nasal epithelial cells were obtained
by nasal brushing, as previously described,20,22 from enrolled CF patients and from
five non-CF consenting healthy volunteers. Brushes with cells were rapidly
transferred in 15-ml sterilized tubes containing RPMI1640 medium (Invitrogen,
Carlsbad, CA, USA) with 1% penicillin-streptomycin (Lonza Group LTD, Basel,
Switzerland, 17-602E). The tubes were incubated at 37 °C for 2 h on a thermal
shaker, to remove all cells from brushes. Cells were centrifuged at 800 × g
(2000 rpm) for 20 min. The supernatant fractions were discarded and the cell pellet
treated with 150 ml of trypsin-versene (EDTA) solution (Lonza, 17–161) for 4 min at
37 °C to disaggregate possible cell clusters. Cells were placed in CELLC T-25 flasks
(Sarstedt Ltd, CS300) with BEGM medium after centrifugation at 800 × g (2000 rpm)
for 10 min. Non-specific epithelial cells were removed with daily medium changes.
In vitro studies before in vivo treatment: Before in vivo treatment (week 0)
nasal epithelial cells were freshly collected by nasal brushing from the patients
enrolled in the study. Nasal brushing from 45 of 52 patients provided a sufficient
number of cells for in vitro evaluation. Nasal cells were cultured in vitro for 18 h with
250 μM cysteamine (Sigma Aldrich, M9768) or 80 μM EGCG (Sigma Aldrich,
E4143) or cysteamine plus EGCG, and then kept in culture with medium alone up to
48 h, in the presence or absence of EGCG, as described.20 We tested the rescue of
CFTR function by measuring the rate of halide efflux, and the amount of mature
bend C CFTR protein by surface biotinylation and western blot as previously
described.20
Ex vivo analysis during in vivo treatment: Samples collected at week 0 and
at each point through the study were immediately used to assess CFTR function
and protein levels, BECN1 and SQSTM1/p62 proteins and cytokine expression. The
values were compared with those from five non-CF healthy volunteers.20
Procedures
Halide efflux analysis. The analysis of halide efflux was performed in nasal
cells, by the iodide-sensitive fluorescent indicator, SPQ (Molecular Probes/
Invitrogen, Carlsbad, CA, USA, M440), as previously described.20 In brief, the
cells were incubated for 20 min at 37 °C in a humidified chamber with 5% CO2 with
the iodide-sensitive fluorescent indicator SPQ, as described (REF). The SPQ-
loaded cells were mounted on a LSM510 Meta confocal microscope (Zeiss, Milan,
Italy) with a 37 °C heated stage and perfused with iodide buffer for 5–8 min.
Changes in CFTR-mediated SPQ fluorescence were observed at the 445 nm
wavelength in response to excitation at 340 nm during perfusion at 37 °C in nitrate
buffer replaced with 130 mM NaNO3 (Sigma Aldrich, S8170) with 20 μM forskolin
(Fsk; Sigma Aldrich, F6886) plus 100 μM IBMX (Sigma Aldrich, I5879) and
fluorescence intensity measured for a further 10–12 min. Signals were recorded at
30-s interval. For each minute the average of the fluorescence intensity was
measured from 50 cells for population per coverslip and the peak of halide efflux
rate (usually after Fsk plus IBMX adding) of cells was calculated in accordance with
the Stern-Volmer relationship.41 The rates were calculated using SigmaPlot Version
7.1 for each mean fluorescence trace for each time point generated from the 50
cells examined per population per coverslip.41–45
Immunoblot analysis, cell surface biotinylation assay and
membrane fractionation. The proteins were obtained from nasal epithelial
cells. To detect CFTR protein, a large amount (120 μg) of protein was loaded.
Western blot was performed as previously described20 with antibodies against the
following proteins: BECN1, CFTR, β actin, SQSTM1/p62. The antibodies
specifications are reported in Supplementary Table S16.
Insoluble pellet was obtained by centrifugation at 9000 × g at 4 °C for 20 min after
lysis and dissolved 5 times in sample buffer, boiled at 95 °C for 5 min and resolved on
a polyacrylamide gel for western blot analysis of SQSTM1/p62, as described.20
The densitometric analysis was performed by Image J software and each data
point was expressed as the mean±S.D. of independent experiments.
Cell-surface proteins were biotinylated and the PM fraction was collected to detect
mature CFTR band C at the PM. Sulfosuccinimidyl-6-(biotinamido) hexanoate (sulfo-
NHS-LC-Biotin, Pierce, Rockford, IL, USA, 21335), was dissolved at 1 mg/ml in PBS
(Gibco/Thermo Scientific Milan, Italy, 18912–014, pH 8.2), as described.22 After
homogenization with a Potter-Elvehjem pestle, the cells were centrifuged at 2300 × g
for 15 min at 4 °C. Supernatant fractions that contain the cytoplasmic and PM
fractions were centrifuged 1 h at 16 000 × g at 4 °C; the pellet that contains the intact
membrane, was solubilized in Buffer A (20 mM Tris-HCl, pH 7.4, 2 mM EDTA, 20 mM
2-mercaptoethanol, 1 × PMSF, 1 μg/ml inhibitor protease cocktail (Sigma Aldrich,
P8340)+1% Triton X-100 (Sigma Aldrich, X- 100-RS) and centrifuged 1 h at
60 000 × g in the ultracentrifuge. The supernatants were representative of PM
fraction. Equivalent amounts of protein (500 μg) were used for streptavidin-agarose
affinity isolation (Pierce, Rockford, IL, USA, 20349). Biotinylated proteins of PM
immunoblotted against CFTR or FLOT1. The densitometric analysis was performed
by Image J software and each data point was expressed as the mean± S.D. of
independent experiments.
Measure of TNF-α and CXCL8 expression levels in nasal
brushing. RNA extraction was performed as detailed above. For human
samples, thermocycling consisted of an initial polymerase activation step at 95 °C
for 5 min, amplification was performed with 40 cycles of 95 °C for 15 s, 60 °C for
10 s and 72 °C for 20 s with data acquisition at this stage and the reaction finished
by the built in melt curve. Expression levels of genes were normalized to the
housekeeping gene GAPDH in the same sample. The specifications of primers are
reported in Supplementary Table S15.
Measure of TNF-α and CXCL8 levels by ELISA in sputum. Sputum
samples were diluted 1 : 2 with PBS and digested with 1 U/μl of DNAse for 4 h at
37 °C. The supernatants were collected and stored at − 80 °C until usage. The samples
were then centrifuged at 800 × g for 10 min and the supernatants used to measure
TNF-α and CXCL8 levels by means of standard ELISA kits (R&D Systems,
Minneapolis, MN, USA), according to the manufacturer’s instructions, as reported.16,46
Samples were read in triplicate at 450 nm in Microplate Reader (BioRad, Milan, Italy)
using Microplate Manager 5.2.1 software. Values were normalized to protein
concentration evaluated by Bradford analysis.
Statistical analysis. Categorical variables are presented as proportion (%)
and continuous variables as mean (and S.D.) when normally distributed or median
(and IQR) when not.
Mice: All laboratory tests on mice were performed at least in triplicate. Between-
group comparisons were evaluated by one-way analysis of variance, applied to mean
(or median) values of continuous variables; post hoc comparisons were made using
Bonferroni correction, when appropriate. We set the level of significance at Po0.05.
Humans: An ethical committee (including statisticians) validated the plan of the
study. Normality of data distribution was tested and the effects of treatment in CF
patients on either sweat chloride or nasal CFTR function were analyzed by repeated
ANOVA, comparing the means of variables measured at different times of treatment,
and during the 4-week follow-up period, as previously described.20 For brushed
nasal cells all laboratory tests on cells were performed at least in triplicate.
According to Šidák correction for multiple comparisons, each comparison47 was
considered significant if P-values (for two-tailed test) were o1 1 að Þ1=n ,
where α is the overall type I error probability and n is the number of
comparisons. Values registered at the end of combination treatment,
either 4-week or 8-week treatment, with cysteamine plus EGCG were
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pooled for the analysis. The Fisher's test was used to assess the
proportion of subjects who fulfilled the primary end point between
treated (at the end of the combination treatment) and untreated
(during an observational period of the same duration) groups for
variation of CFTR function (see the exact definition of primary end
point above).
For secondary end points a paired T-test was used to evaluate differences
between two time points in the same group of patients. We used a Fisher's test to
evaluate differences between groups (treated versus untreated, as detailed above) for
rescue of autophagy, cytokine values in both nasal brushing and sputum, and
absolute change in ppFEV1. For prediction tests and biomarkers, unpaired T-tests
were uses to compare two groups of quantitative data, correlation tests (Pearson’s
and Spearman’s) were used to search for relationship between quantitative data,
linear model were used to search for causal relationship between quantitative data.
ROC curve analysis was applied to analyze potential biomarker for treatment
response. Data was processed through EXCEL (versions 2010). All data processing
and analyses were carried out with SAS statistical software (version 9.2; SAS
Institute, Cary, NC, USA) and R software (version 3.0.2).
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